Hibiscus Sabdariffa

PreclinicalBiologic

AAin Shams University

Hibiscus Sabdariffa is one of 18 biologic programs targeting Xerostomia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

XerostomiaActive, not recruiting

XerostomiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Xerostomia

#DrugCompanyPhaseTrials

Isopto Carpine

AAdvanz Pharma

Approved

3 2

Decadron

AAspen Global Incorporated

Approved

—3

Ethyol

LLegacy Health System

Approved

—4

Evoxac

CCosette Pharmaceuticals, Inc.

Approved

1 5

Biotene

UUniversity of Southern California

Approved

1 6

Aloevera

GGovernment Dental College and Research Institute, Bangalore

Phase 3

1 7

Mesenchymal Stem Cell

RRohto Pharmaceutical Co., Ltd.

Phase 2

1 8

Stem Cells

KKang Stem Biotech Co., Ltd.

Phase 2

1 9

Amifostine Trihydrate

GGynecologic Oncology Group

Phase 2

1 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Xerostomia1 trial

The Efficacy of Hibiscus Sabdariffa in Xerostomia

Recruiting·—·N/A·NCT06413550·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hibiscus Sabdariffa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hibiscus Sabdariffa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hibiscus Sabdariffa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ain Shams University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAin Shams University

Hibiscus Sabdariffa

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Xerostomia1 trial

References

Drug Info

Quick Facts

Related News